Effect of High-Dose Thiamine and Pyridoxine on Advanced Glycation End Products and Other Oxidative Stress Markers in Hemodialysis Patients: A Randomized Placebo-Controlled Study

Abstract

To study the effect of high doses of thiamine (250 mg/day) and pyridoxine (200 mg/day) supplementation on plasma levels of advanced glycation end products and other oxidative stress markers in hemodialysis patients. An interventional survey. This study was conducted at an outpatient nephrology clinic. INTERVENTION AND PATIENTS: We performed a randomized placebo-controlled study over 8 weeks in 50 patients (53% men, age 52.9 +/- 3.4 years) on regular hemodialysis. The patients were divided into 2 groups of 25 patients in each arm. Before starting the study, the patients in both groups were matched by age, gender, inflammatory profile (plasma interleukin [IL]-6 and high-sensitivity C-reactive protein [hsCRP]), and nutritional status (subjective global assessment and protein nitrogen appearance). In all, 40 of 50 patients completed the study (19 patients in the vitamin group and 21 in the placebo group). Serum albumin, plasma hsCRP, IL-6, advanced oxidation protein products, pentosidine and 8-hydroxy-2'-deoxyguanosine were measured before and after treatment in each group. In both groups, over 8 weeks of follow-up, no significant differences could be observed in oxidative stress, inflammatory, or nutritional markers. There was no evidence showing that high doses of thiamine and pyridoxine affects oxidative stress in hemodialysis patients.